Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2006

View Archived Issues

Snapshots of histone deacetylases (HDACs) as novel effective targets in cancer therapy: Part I

Galenea to focus on development of drugs to treat CNS diseases

DOR advances mucosal vaccine for botulinum toxin

PPARgamma agonists in cancer highlighted at AACR

Dosing completed in phase I study of Sinovac's H5N1 vaccine

Promising results seen with denosumab in postmenopausal osteoporosis

STRIDE studies reveal effects of sitaxsentan in pulmonary arterial hypertension

MPC-7869 beneficial in patients with mild, but not moderate, Alzheimer's disease

MBP-8298 delays multiple sclerosis progression

XP-13512 significantly improves restless legs syndrome

Garenoxacin effective in community-acquired pneumonia caused by resistant strains

Enrollment ahead of schedule in phase III study of VP-4896 for Alzheimer's

ProMetic begins enrollment in phase Ib/II study of PBI-1402

AlphaRx grants Proprius rights to Indaflex

Emisphere expands enrollment in phase II oral insulin trial

Phase II study of Aridol for COPD completes enrollment

Myriad Genetics and Abbott establish broad drug discovery collaboration

Schering-Plough selects compound from Pharmacopeia collaboration

Tostrex completes European MRP

Expansion of Biolex's collaboration with Medarex

Affymax studies Hematide in pure red cell aplasia patients

Amigal recommended for European orphan drug status for Fabry's disease

Preclinical update on ARRY-142886

Small-molecule pan-ErbB inhibitor selected by J&J as development candidate

Novel analgesic agents reported in recent patents

New AIDS diagnostic developed by Bio-Rad Pasteur

Recent patents describe novel agents for neurological disorders

mTOR inhibitor from Biotica shows potential for glioblastoma multiforme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...